How do you take that first step and balance clinical duties with non-clinical interests? What specific advances in biotech could have the potential to revolutionize clinical treatment in the near future? What factors are you optimizing for in your career plan? Join this episode as Dr. Sam Kessel answers these questions and more and shares his story!

Sam completed his intern year in internal medicine. He was an associate for multiple angel networks, performing part-time due diligence on medical startups during medical training. He then went on to become a Consultant at LEK Consulting. He is now an associate at Locust Walk, where he works with various biotech companies using cutting-edge technologies to help them find partners and funding. He hosts the Nucleate Signal podcast and interviews folks who are the next generation of leaders in biotech.

He got his Bachelor's from Tufts University, MD from the University of Virginia School of Medicine, and MBA from the University of Virginia Darden School of Business.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

How can we, as MDs, ensure better representation of low-resource countries in the digital healthcare movement? What are the means to enhancing healthcare access through AI-led digital acceleration? How can you generate building blocks to guide your entrepreneurial journey? Dr. Alice Jacobs, CEO of Convergence Group, answers all these questions and more.

Alice is a physician and entrepreneur. She leads the Convergence Group, which works on improving access to and delivery of healthcare through AI-led digital acceleration. She founded her first company, IntelligentMDx, after losing a patient from a staph infection. She has worked with leading venture funds, including Third Rock Ventures/MIT/Bob Langer, GE Ventures, and GreyBird Ventures. She spent two years as an Entrepreneur-in-Residence at Caltech, guiding efforts to build the next generation of deep technology solutions.

She was recognized by Scientific American as one of the top 50 innovators and by the World Economic Forum as a Young Global Leader, a 40 under 40 award by the Boston Business Journal, and for Healthcare Innovation in Clinical Diagnostics by Frost & Sullivan.

She holds a BA in Art History, a BS in Biological Sciences from Stanford with Honors in Developmental Neurobiology, and an MD from Harvard Medical School.

What did you optimize for when choosing the first position outside the clinical path? What are the challenges that M.D.s could encounter when leaving clinical medicine? What is the role of immigrant mentality in building risk tolerance? Dr. Shehnaaz answers!

Dr. Shehnaaz Suliman is a visionary physician, drug developer, and dealmaker with over 25 years of experience reshaping the biotech landscape. She is C.E.O. and board member at ReCode Therapeutics, an integrated genetic medicines company located in California that works on developing disease-modifying therapeutics using its powerful L.N.P. delivery technology to target organs and tissues beyond the liver. She was formerly president and C.O.O. at Alector, a clinical-stage biopharmaceutical company. Her professional experience began in 2001. Since then, Shehnaaz has changed six roles and seven companies, such as Theravance Biopharma, Genentech, Roche Partnering, Gilead Sciences, Lehman Brothers and Petkevich & Partners, Ultragenyx Pharmaceutical, and 10X Genomics.

Dr. Suliman received her M.D. from the University of Cape Town Medical School, South Africa. She also holds an M.B.A., with distinction, and an M.Phil. in development studies from Oxford University, where she was a Rhodes Scholar. She was named one of the 2017 Fiercest Women in Life Sciences and one of the National Diversity Council’s Power 50 in 2021 (Most Influential Women in Business). Recently, Shehnaaz was featured on the 2023 Forbes 50 over 50 and was recognized as the 2023 Women of Influence by the Silicon Valley Business Journal.

Dive into a seasoned venture capitalist's mind as they look at today's landscape! Dr. Farzad Soleimani is sharing valuable insights on:

Farzad is the Healthcare Partner at 1984 Ventures, having seeded companies such as Trusted Health, Deep Scribe, Health Note, and Signos. He is the founder of eTherapi, a pioneering telemedicine company, and the founding co-director of the Texas Medical Center Biodesign Innovation Program. He started his investing career at MohrDavidow Ventures and continued to work at a number of innovation startups, such as Pocket Naloxone, Hansen Medical, and IGAN Biosciences.

Farzad completed his residency training at Baylor and earned his MBA, MD, MS, and BS from Stanford University. He is on faculty at Baylor Medical School, Rice Business School, and Rice Bioengineering Department.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

Unlocking Hyper-Personalized Learning in Medicine! Join us for an insightful chat with Dr. Sievert Weiss, co-founder of AMBOSS. Discover how digital tools create tailored learning experiences for aspiring medical professionals.

Sievert is a physician by training and a self-taught med-ed-tech co-founder who is notoriously curious to explore ways to improve healthcare and has an interest in public and global health issues. In 2012, right after graduation, he co-founded AMBOSS, a German medical technology company. Their mission is to improve global health by empowering physicians worldwide to apply the best care possible. Today, more than 2 million healthcare professionals in over 170 countries rely on AMBOSS. Sievert studied medicine in Germany, Portugal, and Brazil. He studied at the University of Göttingen.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

How should physicians navigate the distinction between physicians as citizens vs. physicians as professionals as it relates to policy advocacy? How can we rally different social norms and regulatory frameworks toward the intended change point? How would clinical practice ignite and foster advocacy work?

In this episode, Dr. Ana Cristina González Vélez answers all these questions and delves into her journey of advocating for women’s reproductive rights! 

Ana Cristina González Vélez is a Colombian reproductive rights activist and medical doctor. She is a known international researcher, advocate, and expert in the field of sexual and reproductive health as well as gender equality. She is the founder and active member of La Mesa por la Vida y la Salud de las Mujeres, Colombia, the team coordinator of the Feminist group Mercosur, and the founder and coordinator of the Medical Group for the Right to Decide in Colombia.

Ana holds an MD from Pontifical Bolivarian University in Colombia, a master’s degree in social health research from the Center for Study on State and Society in Buenos Aires, Argentina, and a Ph.D. in Bioethics from Fiocruz Foundation in Brazil. She is currently a Fellow at the Harvard LEAD Fellowship for Promoting Women in Global Health.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

How can you get involved in shaping healthcare policy rather than just be shaped by it? How can policy work make you a better clinician and a better advocate for your patients? What are hospital "never events"? 

Join our 47th episode featuring a panel discussion with Dr. Farzad Mostashari and Adam Beckman.

Dr. Farzad Mostashari has spent his career at the forefront of healthcare policy and health information technology. He is the Co-Founder and CEO of Aledade, a primary care enablement company that partners with independent private care practitioners to transition to value-based care and, as a result, maintain their independence. Dr. Mostashari received his MD from Yale University School of Medicine and his Masters in Population Health from Harvard TH Chan School of Public Health. He did an internal medicine residency at Massachusetts General Hospital.

Adam Beckman was a joint MD-MBA student at Harvard Medical School and Harvard Business School. Adam took a leave of absence from his MD/MBA program at Harvard Medical School in 2021 to serve as a special advisor to US Surgeon General Vivek Murthy. In 2022, he was featured on Forbes' 30 healthcare leaders under 30. Adam holds a Bachelor Of Arts/Science from Yale University. He finished his MD-MBA programs at Harvard Medical School and Harvard Business School in May 2023.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

What are outcome-based payment agreements or VBAs, and how can MDs develop innovative financing models? What do the next few years hold for VBAs in therapeutics and diagnostics? How can we mentor young doctors looking to venture off the beaten path? Join us as Dr. Micahel Sherman answers these questions and discusses mentorship, supporting VBAs, the Inflation Reduction Act, and many other topics.

Michael is currently a Venture Partner at RA Capital. Michael is formerly an executive vice president and the chief medical officer at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Michael is known as a pioneer in developing outcomes-based payment agreements and bringing novel interventions to patients. He signed the first outcomes-based contract for a gene therapy in the US.

Michael holds an M.D. from Yale University, an MBA from Harvard Business School, and master’s and bachelor’s degrees from the University of Pennsylvania.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

How important is it for physicians to be translators who can merge technology with healthcare? What are the characteristics that make the Singaporean healthcare system unique on a global level? How can we foster a better teamwork mentality across physicians? In this episode, Dr. Zubin Daruwalla explores these topics and more!

Zubin Daruwalla is the PwC Singapore Health Industries Leader and sits on PwC’s Global Health Leadership Team. He is also a Co-Founder of HiruX. He has delivered over 100 talks and presentations, including multiple keynotes in more than 12 countries and across 5 continents.

After graduating with honors from the Royal College of Surgeons in Ireland in 2005, Zubin commenced and continued his practice of medicine in Dublin. He subsequently pursued a career in orthopedic surgery. He was awarded the Membership of the Royal College of Surgeons in Ireland (MRCSI) in 2008, followed by a Master's in Orthopedic Surgery (MCh, Orth) in 2010.

Named one of the most influential and emerging voices in the global health industry in 2021 and the Top 50 Most Influential Voices of Healthcare in 2022, he hopes to help bridge the gap between the technical and clinical sides of digital health.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!

Join us as Lincoln Nadauld, CEO of Culmination Bio, delves into the crucial role of genomics-powered precision medicine in Oncology research. Discover the main challenges hindering the adoption of precision medicine in clinical oncology. Gain insights on effectively managing your time between clinical medicine and the industry. Don't miss Lincoln's inspiring journey!

Lincoln Nadauld is the CEO of Culmination Bio, a biotech company leveraging unique data sets from diverse biosamples containing vast biological data enriched with clinical data.

He was VP and Chief of Precision Health and Academics at Intermountain Healthcare, where he led precision health across 24 hospitals and 200 clinics, overseeing Graduate Medical Education. He is the co-founder of Clarified Precision Medicine as well as Guidance Genome.

Lincoln graduated from Bountiful High School. He played rugby while getting his undergraduate degree at BYU, his Doctor of Medicine, and his Doctor of Philosophy from the University of Utah. Then he did his clinical training in oncology at Stanford University.

We volunteer our time and money to make this content freely available – if you enjoy our content and find it helpful, you can support us by buying us a coffee here!